Ulcerative Colitis Therapeutics Market to Reach $12 Billion by 2027 - Arizton

According to Arizton's latest research report, ulcerative colitis market is expected to grow a at CAGR of 8.7% during 2022-2027. With more than 150+ molecules in various stages of development, it is expected that new vendors are likely to enter the market with novel mechanism of action and better safety and efficacy profiles compared to the existing patented commercial drugs for treating ulcerative colitis.

Click Here to Download the Free Sample Report: https://www.arizton.com/request-sample/3428

The Ulcerative colitis report provides a detailed analysis of the drugs available for the treatment of Ulcerative colitis. The report covers a detailed drug description including drug name, sponsor name, route of administration, molecule type, mechanism of action of the drug, clinical studies, NDA approvals, Ulcerative colitis (Ulcerative colitis) collaborations, licensing, mergers and acquisition, designations, and other product-related details.
Presently, the Ulcerative colitis market comprises of patented drugs as well as off-label drugs. Off-label drugs used in treatment of Ulcerative colitis includes 5-aminosalicyclic acid(5-ASA) including mesalamine, olsalazine and sulfasalazine; corticosteroids including Prednisone, Prednisolone & Methy prednisol; Immunosuppressants including Azathioprine, 6-Mercaptopurine, Cyclosporine & Tacrolimus. The US is expected to account for a significant share of the global Ulcerative colitis treatment market during the forecast period.

MARKET DRIVERS
• The Ulcerative colitis mortality rate is higher in developing countries, due to improper detection at early stages of the disease.
• Increased incidence of Ulcerative colitis cases will increase expensive long-term prescriptions.
• Adoption of advanced technologies in ulcerative colitis treatment and rise in the number of treatments will boost the Ulcerative colitis treatment market

Key Vendors
• Johnson & Johnson
• AbbVie Inc (AbbVie)
• Takeda Pharmaceutical Co Ltd (Takeda)
• Pfizer Inc (Pfizer)
• Bristol-Myers Squibb
• EA Pharma
• Eli Lilly and Company
• InDex
• Reistone Biopharma Co. Ltd.
• CellTrion

MARKET SEGMENTATION
Drug Class
• TNF-Alpha inhibitors
• 5-Aminosalicylates
• Corticosteroids & Others
Gender Type
• Men
• Women
Disease Type
• Total Colitis
• Left-sided Colitis & Proctitis
Geography
• North America
o US
• Europe
o France
o Germany
o Italy
o UK
o Spain
• APAC
o China
o Japan

To know more: https://www.arizton.com/market-reports/ulcerative-colitis-market

ABOUT ARIZTON:  

Arizton Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services. 

We offer comprehensive market research reports on industries such as consumer goods & retail technology, automotive and mobility, smart tech, healthcare, and life sciences, industrial machinery, chemicals, and materials, IT and media, logistics and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts. 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports. 

Arizton Advisory and Intelligence
Call: +1-312-235-2040 
          +1 302 469 0707 

This release was published on openPR.